Gerresheimer’s June Verdict: A 70% Rally Built on Borrowed Time

The numbers tell a story of dramatic recovery. Gerresheimer’s stock has surged more than 70% from its February nadir of €15.57, touching €28.04 and reclaiming its 200-day moving average for the first time in months. On a 30-day view, the gain clocks in at roughly 57%. Yet for anyone who bought at last May’s 52-week high of €64.40, the paper loss still exceeds 58%. This is a rally with deep caveats.

The real engine behind the rebound has little to do with operations. Gerresheimer secured a critical reprieve from creditors holding €870 million in Schuldschein loans: 96% of lenders agreed to extend maturities until the end of September, and banks have temporarily waived financial covenant tests. That staves off an immediate liquidity crunch, but it does nothing to resolve the underlying crisis.

The June Deadline That Changes Everything

Gerresheimer still has not published its audited annual report for 2025. A second external audit firm is now combing through business transactions from both 2024 and 2025, and management targets a release in June 2026. Until that audit opinion lands, institutional investors remain locked out — a key reason the company was ejected from the SDAX index. Fund managers need a clean audit certificate before they can touch the stock.

Alongside the annual report, Gerresheimer plans to publish its first-quarter 2026 results. The annual general meeting has been postponed indefinitely, and the half-year report is scheduled for July 14. The entire financial calendar hinges on that June audit.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Accounting Scandal Widens on Multiple Fronts

The regulatory storm is intensifying. Germany’s audit oversight body, APAS, has opened professional misconduct proceedings against KPMG, the auditor that issued an unqualified opinion on Gerresheimer’s 2024 financial statements. At the centre of the probe are roughly €35 million in so-called bill-and-hold transactions — deals where Gerresheimer invoiced customers but never shipped the goods, yet still booked the revenue.

Shareholder advocacy group DSW is now exploring damages claims against former CEO Dietmar Siemssen and ex-CFO Bernd Metzner, and is considering bringing in a litigation financier. The audit committee of the supervisory board is also under scrutiny.

For 2025, Gerresheimer expects non-cash impairment charges of €220 million to €240 million, tied to projects at its Sensile Medical unit and assets at the Chicago Heights glass plant. That facility will close on September 30, eliminating 172 jobs as production shifts to Italy and India.

A Turnaround Plan Under Pressure

Management rejected an informal takeover bid from US rival Silgan at €41 per share in April, opting instead to pursue an independent recovery. The sale of US subsidiary Centor, advised by Morgan Stanley, has already drawn a double-digit number of interested parties.

Gerresheimer at a turning point? This analysis reveals what investors need to know now.

Despite the turmoil, Gerresheimer is standing by its 2026 guidance: revenue of €2.3 billion to €2.4 billion, an adjusted EBITDA margin of 18% to 19%, and moderately positive free cash flow. The forecast is conditional on a favourable outcome from the BaFin investigation and successful credit negotiations.

The stock’s current level — roughly €28 — reflects hope that the June audit will clear the path for institutional re-engagement. But with the accounting cloud still overhead, the rally remains a bet on a single event. If the audit passes, the biggest hurdle falls. If it does not, the next leg down could be brutal.

Ad

Gerresheimer Stock: New Analysis - 8 May

Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Gerresheimer analysis...

en | DE000A0LD6E6 | GERRESHEIMER’S | boerse | 69292837 |